{
    "nct_id": "NCT06068543",
    "official_title": "A Phase 2 Randomized Controlled Trial of Epigallocatechin-3-Gallate (EGCG) on Frailty and Inflammation in Older Survivors of Cancer",
    "inclusion_criteria": "1. Be age 65 or over.\n2. Be diagnosed with stage I-III Cancer\n3. Have completed curative intent treatment ≤10 years prior to screening Patients on the following endocrine therapies are allowed to enroll (Anastrozole,Leuprolide acetate, and Bicalutamide)\n4. Have a Fried's Frailty Score (FFS) of ≥ 1\n5. Able to provide informed consent\nHealthy volunteers allowed\nMust have minimum age of 65 Years",
    "exclusion_criteria": "1. Have chemotherapy or other systemic cancer treatment planned to occur during the study period.\n2. Have abnormal liver function tests (ALT, AST, and bilirubin) per most recent available lab test (within 3 months of screening)\n\n   * 3 times institutional upper limit of normal for ALT and AST\n   * 1.5 times institutional upper limit of normal for bilirubin\n3. Have uncontrolled or unmanaged liver disease.\n4. Consume more than 6 cups of green tea per day.\n5. Have known allergies to caffeine.\n6. Be diagnosed with a major psychiatric illness requiring hospitalization within the last year.\n7. Be diagnosed with dementia.\n8. Cannot provide informed consent due to lack of decision-making capacity (as determined by the patient's oncologist).",
    "miscellaneous_criteria": ""
}